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OBJECTIVE — Toindividuateanovelsex-speciﬁcindex,basedonwaistcircumference,BMI,
triglycerides, and HDL cholesterol, indirectly expressing visceral fat function.
RESEARCHDESIGNANDMETHODS — Visceraladiposityindex(VAI)wasﬁrstmod-
eled on 315 nonobese healthy subjects. Using two multiple logistic regression models, VAI was
retrospectively validated in 1,498 primary care patients in comparison to classical cardio- and
cerebrovascular risk factors.
RESULTS — All components of metabolic syndrome increased signiﬁcantly across VAI quin-
tiles. VAI was independently associated with both cardiovascular (odd ratio [OR] 2.45; 95% CI
1.52–3.95; P  0.001) and cerebrovascular (1.63; 1.06–2.50; P  0.025) events. VAI also
showed signiﬁcant inverse correlation with insulin sensitivity during euglycemic-
hyperinsulinemic clamp in a subgroup of patients (Rs  0.721; P  0.001). By contrast, no
correlations were found for waist circumference and BMI.
CONCLUSIONS — Our study suggests VAI is a valuable indicator of “visceral adipose func-
tion” and insulin sensitivity, and its increase is strongly associated with cardiometabolic risk.
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V
isceral obesity (1) is associated with
increased adipocytokine produc-
tion, proinﬂammatory activity (2),
deterioration of insulin sensitivity (3), in-
creased risk of developing diabetes,
“high-triglyceride/low–HDL cholesterol
dyslipidemia,” hypertension, atheroscle-
rosis, and higher mortality rate (4–7).
The identiﬁcation of a routinely applica-
ble indicator for the evaluation of visceral
adipose function, with higher sensitivity
and speciﬁcity than classical parameters
(such as waist circumference [WC], BMI,
and lipids), could be useful for cardio-
metabolic risk assessment. We here ex-
trapolate a novel sex-speciﬁc index based
on WC, BMI, triglycerides (TGs), and
HDL(visceraladiposityindex[VAI]),able
toestimatethevisceraladipositydysfunc-
tion associated with cardiometabolic risk.
RESEARCH DESIGN AND
METHODS— The study was ap-
provedbytheInstitutionalReviewBoard,
University of Palermo.
Subjects
The Alkam Metabolic Syndrome (Alka-
MeSy) Study database including 13,195
primary-care patients was used (see on-
line Appendix 1, available at http://
care.diabetesjournals.org/cgi/content/
full/dc09-1825/DC1). A total of 1,498
subjects were selected based on availabil-
ity of full information listed in Table 1.
Because data were recorded anony-
mously, no individual informed consent
was needed.
Model of adipose distribution and
VAI formulas
A total of 315 healthy subjects with BMI
between 20 and 30 kg/m
2 were further
selected from the 1,498 primary-care pa-
tients to calculate a model of adipose dis-
tribution (MOAD). To correct MOAD for
fat function, TG (mmol/l) and HDL
(mmol/l) levels were introduced in the
formula. This was deﬁned as VAI:
Males: VAI 
WC
39.68  (1.88  BMI)

TG
1.03 
1.31
HDL
Females: VAI 
WC
36.58  (1.89  BMI)

TG
0.81 
1.52
HDL
assuming VAI  1 in healthy nonobese
subjectswithnormaladiposedistribution
and normal TG and HDL levels (supple-
mental Appendix 2).
Magnetic resonance imaging
To validate MOAD, magnetic resonance
imaging (MRI) was prospectically per-
formed on 26 metabolically healthy pa-
tients (supplemental Appendix 3).
Euglycemic-hyperinsulinemic clamp
Euglycemic-hyperinsulinemic clamp was
prospectically performed in 74 patients
(supplemental Fig. 1, available in the on-
lineappendix).Rateofperipheralglucose
utilization(Mvalue)wascalculatedbydi-
viding glucose infused during the last 40
by body weight measured in kilograms
(milligrams per kilogram per minute) (8).
Statistical analysis
Data were analyzed using SPSS 13.0 for
Windows. Univariate correlations were
performed using the nonparametric test
(Spearman, Rs). Binary logistic regression
was performed to explore possible deter-
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events: “coronary heart disease and/or
myocardial infarction” and “transient
ischemic attack and/or ischemic stroke.”
Independent variables showing a P value
0.10 in a univariate analysis were en-
tered in one single step. Receiver-
operating characteristic (ROC) analysis
was used to assess whether VAI associates
with cardio- and cerebrovascular events
in comparison to WC, BMI, and TG-to-
HDL ratio, considered separately. Differ-
ence among C statistics of VAI, BMI, WC,
and TG-to-HDL ratio was calculated by
Hanley and McNeil’s method.
RESULTS — To verify whether MOAD,
WC, and BMI correlated with visceral
adipose tissue (VAT) and subcutaneous
adipose tissue (SAT), we validated each
index with abdominal MRI. MOAD
showed signiﬁcant correlation with VAT,
both regarding area (Rs  0.437, P 
0.025) and volume (Rs  0.744, P 
0.001), but not with SAT.
The1,498primary-carepatientswere
furthersubdividedintoVAIquintiles.Age
and number of patients with metabolic
syndrome, diabetes, high blood pressure,
low HDL, high TGs, LDL cholesterol
3.37 mmol/l, coronary heart disease
and/or myocardial infarction, and tran-
sient ischemic attack and/or ischemic
stroke increased signiﬁcantly across VAI
quintiles (supplemental Table 1).
Binary logistic regression models
showed VAI is an indicator of visceral fat
dysfunction independently associated to
coronary heart disease and/or myocardial
infarction and transient ischemic attack
and/or ischemic stroke. Among all vari-
ables examined, only VAI, age at the time
of event, smoking, and male sex were in-
dependently correlated to cardiovascular
events. VAI and age at the time of event
were independently associated with cere-
brovascular events (Table 1).
Toverifythepossiblerelationshipbe-
tween insulin sensitivity and VAI, WC,
and BMI, data from euglycemic-
hyperinsulinemic clamps were retrospec-
tively analyzed. M values during the
clamp showed signiﬁcant inverse correla-
tion with VAI (Rs  0.721; P  0.001).
No correlation was found between M
value and either WC or BMI (supplemen-
tal Fig. 1).
Concerning cardiovascular risk, ROC
curve analysis showed signiﬁcant differ-
ences in C statistics between VAI and BMI
(P0.032;SE0.06;95%CI0.01–0.26),
WC (P  0.031; SE 0.06; 95% CI 0.01–
0.26), and TG-to-HDL ratio (P  0.005;
SE 0.04; 95% CI 0.03–0.19). Regarding
cerebrovascular risk, signiﬁcant differ-
ences were found between VAI and BMI
Table 1—Maximum likelihood estimates of logistic regression function related to the dichotomic dependent variables “coronary heart disease
and/or myocardial infarction” and “transient ischemic attack and/or ischemic stroke”
Regression
coefﬁcient SE Wald P OR 95% CI for OR
Coronary heart disease and/or myocardial
infarction
Intercept 10.661 1.990 — 0.001 — —
Presence of metabolic syndrome* 0.390 0.697 0.314 0.575 1.47 0.37–5.79
Total cholesterol 0.004 0.006 0.523 0.470 1.00 0.99–1.01
Diabetes or fasting glucose 5.6 mmol/l† 0.904 0.604 2.241 0.134 0.40 0.12–1.32
High blood pressure* 0.720 0.503 2.089 0.148 2.07 0.77–5.54
Current or former smoker 1.400 0.479 8.545 0.003 4.05 1.58–10.36
Male sex 1.388 0.571 5.899 0.015 4.00 1.30–12.28
Age at the time of event 0.053 0.014 14.426 0.001 1.05 1.02–1.08
VAI 0.899 0.243 13.728 0.001 2.45 1.52–3.95
BMI 0.005 0.092 0.003 0.957 1.00 0.84–1.20
WC 0.000 0.031 0.000 0.994 1.00 0.94–1.06
TG-to-HDL ratio 0.605 0.370 2.678 0.102 0.54 0.26–1.12
Transient ischemic attack and/or ischemic stroke
Intercept 6.540 1.863 — 0.001 — —
Presence of metabolic syndrome* 0.556 0.617 0.811 0.368 0.57 0.17–1.92
Total cholesterol 0.004 0.005 0.785 0.376 0.99 0.98–1.00
Diabetes or fasting glucose 5.6 mmol/l† 0.456 0.471 0.936 0.333 1.57 0.62–3.97
High blood pressure* 0.631 0.410 2.377 0.123 1.88 0.84–4.19
Current or former smoker 0.518 0.410 1.595 0.207 1.67 0.75–3.74
Male sex 0.904 0.474 3.638 0.056 2.47 0.97–6.25
Age at the time of event 0.085 0.013 44.53 0.001 1.08 1.06–1.11
VAI 0.489 0.218 5.022 0.025 1.63 1.06–2.50
BMI 0.039 0.087 0.204 0.652 1.04 0.87–1.23
WC 0.049 0.028 2.914 0.088 0.95 0.90–1.00
TG-to-HDL ratio 0.120 0.347 0.120 0.729 1.12 0.57–2.22
*According to Adult Treatment Panel (ATP) III criteria. †According to current American Diabetes Association criteria. Concerning WC, BMI, TGs, and HDL, the
meanvaluesofthe6monthsbeforethebeginningofthestudywereconsidered.Forpatientswhoexperiencedcardio-and/orcerebrovascularaccident,weusedWC,
BMI, TGs, and HDL recorded in the 6 months before the event. Independent variables showing P value 0.10 in univariate analyses were entered in one single step.
Dichotomic variables analyzed through 
2 test or Fisher exact test were as follows: metabolic syndrome, diabetes/fasting glucose 5.6 mmol/l, high blood pressure,
current/formersmoker,andmalesex.QuantitativevariablesanalyzedthroughtheStudent’sttestwereasfollows:totalcholesterol,ageatthetimeofevent,BMI,WC,
and TG-to-HDL ratio.
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and WC (P  0.001; SE 0.05; 95% CI
0.15–0.36), but not TG-to-HDL ratio
(P  0.396; SE 0.03; 95% CI 0.03–0.09)
(supplemental Fig. 2).
CONCLUSIONS — WC is a major
clinical parameter used for the indirect
evaluation of increased visceral fat (9).
Nevertheless, WC alone does not help in
distinguishing between subcutaneous
and visceral fat mass (10). This is a con-
siderable drawback, given that VAT and
notSATplaysadecisiveroleinthegenesis
of cardiovascular sequelae (9,11–13).
Here we identiﬁed an index that could be
used as a surrogate marker of “adipose
tissue dysfunction.” VAI was signiﬁcantly
correlated to all metabolic syndrome fac-
tors and cardio- and cerebrovascular
events. This trend was particularly appar-
ent from the third VAI quintile on, being
moderate for the fourth and severe for the
ﬁfth quintile.
Interestingly, VAI was independently
associated to cardiovascular events, along
with age at the time of event, smoking,
and male sex. This was not observed for
WC, BMI, and the other classical cardio-
vascular risk factors analyzed. Further-
more, VAI and age at the time of event
weretheonlyindependentriskfactorsfor
cerebrovascular events. These ﬁndings
might be explained by the fact that VAI
includes both physical and metabolic pa-
rameters, perhaps indirectly reﬂecting
other nonclassical risk factors, such as al-
tered production of adipocytokines, in-
creased lipolysis, and plasma free fatty
acids, which are not signiﬁed by BMI,
WC,TGs,andHDLseparately.Therefore,
VAI might be a valuable index of both fat
distributionandfunction.Thisisalsocor-
roborated by the correlation between
MOAD and VAT, and between VAI and
insulin sensitivity, evaluated by the hy-
perinsulinemic-euglycemic clamp.
Noteworthy, VAI shows an associa-
tion with M value that is not detected by
WC or BMI alone. This observation con-
ﬁrms that reduction in insulin sensitivity
is associated not only with increased vis-
ceral fat mass, but it is also inﬂuenced by
functional factors, indirectly expressed
by TGs and HDL and by altered VAT-
to-SAT ratio (14). Indeed, this condi-
tion characterized by visceral obesity
and “high-triglyceride/low–HDL choles-
terol dyslipidemia” has been associated
withphysiologicalage-linkedleptinresis-
tance, muscle, and liver insulin resis-
tance, lipotoxic cardiomyopathy, and
generalized endothelial dysfunction (15).
In conclusion, although VAI is not a
diagnostic tool for cardiovascular and ce-
rebrovascular events, the simplicity of
WC and BMI measurement and TG and
HDL assessment, make it an easily appli-
cable index for the evaluation of visceral
fat dysfunction. VAI might therefore be a
useful tool in daily clinical practice and in
population studies for the assessment of
cardiometabolic risk associated with vis-
ceral obesity.
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